BIDOLI, PAOLO

BIDOLI, PAOLO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 127 (tempo di esecuzione: 0.027 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 01 - Articolo su rivista 2022 Carbone M.Abbate M. I.Invernizzi P.Bidoli P.Cortinovis D. +
Novel cytotoxic chemotherapies in small cell lung carcinoma 01 - Articolo su rivista 2021 Cortinovis D.Bidoli P.Lavitrano M. L. +
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 01 - Articolo su rivista 2021 Cortinovis D.Bidoli P. +
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 01 - Articolo su rivista 2021 Bani, MarcoRossi, EmanuelaCortinovis, DiegoRusso, SelenaCicchiello, FedericaCazzaniga, Marina ElenaBidoli, PaoloValsecchi, Maria GraziaStrepparava, Maria Grazia +
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 01 - Articolo su rivista 2021 Bidoli P.Romiti A.Bidoli P.Cazzaniga M.Pasquini E.Pavesi L. +
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 01 - Articolo su rivista 2020 Cortinovis D.Bidoli P. +
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 01 - Articolo su rivista 2020 Bidoli, PaoloInvernizzi, Pietro +
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 01 - Articolo su rivista 2020 Cazzaniga M. E.Bidoli P. +
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 01 - Articolo su rivista 2020 Bidoli, P +
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 01 - Articolo su rivista 2020 Labianca R.Bidoli P. +
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 01 - Articolo su rivista 2020 Bidoli P. +
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 01 - Articolo su rivista 2020 Cortinovis D.Bidoli P. +
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 01 - Articolo su rivista 2020 Cortinovis D.Bidoli P. +
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 01 - Articolo su rivista 2020 Cortinovis D.Bidoli P. +
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 01 - Articolo su rivista 2019 Bidoli P. +
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 01 - Articolo su rivista 2019 Bidoli P +
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 01 - Articolo su rivista 2019 Novello S.Bidoli P. +
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 01 - Articolo su rivista 2019 Bidoli P +
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 01 - Articolo su rivista 2019 Bidoli P +
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 01 - Articolo su rivista 2019 Sharma G. G.Cortinovis D.Villa M.Cordani N.Bidoli P.Pagni F.Piazza R.Gambacorti-Passerini C.Mologni L. +